Perceptive Advisors LLC purchased a new stake in Vical Incorporated (NASDAQ:VICL) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 1,142,858 shares of the biotechnology company’s stock, valued at approximately $2,091,000. Perceptive Advisors LLC owned about 0.06% of Vical at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new stake in Vical in the 4th quarter valued at $3,660,000. BVF Inc. IL acquired a new stake in Vical in the 4th quarter valued at $2,579,000. Renaissance Technologies LLC grew its stake in Vical by 17.2% in the 4th quarter. Renaissance Technologies LLC now owns 677,229 shares of the biotechnology company’s stock valued at $1,239,000 after acquiring an additional 99,420 shares during the period. Stonepine Capital Management LLC acquired a new stake in Vical in the 4th quarter valued at $1,238,000. Finally, Ariel Investments LLC grew its stake in Vical by 9.6% in the 4th quarter. Ariel Investments LLC now owns 637,913 shares of the biotechnology company’s stock valued at $1,167,000 after acquiring an additional 55,669 shares during the period. 55.03% of the stock is currently owned by hedge funds and other institutional investors.
In related news, major shareholder Armistice Capital Master Fund purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were purchased at an average price of $1.43 per share, with a total value of $143,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.88% of the stock is currently owned by company insiders.
A number of equities research analysts recently issued reports on VICL shares. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Vical in a research note on Tuesday, November 21st. Zacks Investment Research raised shares of Vical from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, ValuEngine raised shares of Vical from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $7.00.
COPYRIGHT VIOLATION WARNING: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://sportsperspectives.com/2018/03/13/perceptive-advisors-llc-invests-2-09-million-in-vical-incorporated-vicl.html.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Want to see what other hedge funds are holding VICL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vical Incorporated (NASDAQ:VICL).
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.